Project description
Red light to heal cancer-related inflammation
Conventional chemotherapy and radiotherapy cause significant side effects, including inflammatory conditions such as oral mucositis and dermatitis. To facilitate the treatment of these cancer-related complications, the EU-funded ONCORED project proposes an innovative medical device that relies on photobiomodulation, the application of red light to heal injuries or lesions. Unlike existing devices, the energy and power of the light in the ONCORED system can be controlled depending on the severity of oral mucositis and dermatitis. This leads to more effective treatment and provides relief to cancer patients, reducing their hospitalisation time.
Objective
Today the healthcare system is under great pressure, suffering the challenges brought by cancer and the ageing of the population. Among these challenges is the need for treating oral mucositis (OM) and dermatitis. Both are considered as adverse effects of radio and chemo-therapy employed during the treatment of some cancers, specially leukaemia, head & neck cancers and breast cancers which only generate dermatitis. There is an increase incidence of cancers worldwide, for instance, 842,000 new cases of head and neck cancer were diagnosed in 2017. In addition, leukaemia counts with around 352,000 new cases diagnosed in 2015. And breast cancer is the second most common cancer with 1.7 million new cancer cases diagnosed in the year 2015. These inflammations, occur in 100% of patients that are receiving chemotherapy high‐dose. In views of the situation, there is an urgent need to treat these chemo and radio therapy-associated diseases but the current medical devices are ill adapted since the radiation emitted cannot be controlled in a homogenous way, resulting in an inefficient treatment of OM and dermatitis. In response, NEOMEDLIGHT have developed ONCORED, an innovative medical device based on photo biomodulation for the non-harmful treatment of oral mucositis and dermatitis. ONCORED seeks to simplify workflows at the clinical level enabling the prevention, improvement and removal of OM and dermatitis with homogenous red-light whose dose (energy and power) can be well controlled. Having validated the reliability of the ONCORED system at the pilot scale, we now want to finalise its development and achieve market preparedness. In Phase 1 we aim to carry a Feasibility Study to warrant the project from a technical, commercial and financial point of view. Besides the crucial benefits that it will bring to healthcare, ONCORED will boost the growth of NEOMEDLIGHT, expecting to gain € 27 million gross profit and 16 new people after 5 years in the market, reaching a ROI of 5.49.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesclinical medicineoncologybreast cancer
- medical and health sciencesclinical medicineoncologyhead and neck cancer
- medical and health sciencesclinical medicineoncologyleukemia
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
69100 VILLEURBANNE
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.